Kolexia
Poitou-Bernert Christine Endocrinologie
Poitou-Bernert Christine
Endocrinologie
Hôpital Pitie Salpetriere
Paris, France
321 Activités
691 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Obésité Obésité morbide Syndrome de Prader-Willi Perte de poids Diabète de type 2 Inflammation Poids Insulinorésistance Fibrose

Collaborateurs

Voir plus
Clement Karine
Clement Karine
Hôpital Pitie Salpetriere, Paris, France
Oppert Jean-Michel
Oppert Jean-Michel
Hôpital Pitie Salpetriere, Paris, France
Bouillot Jean-Luc
Bouillot Jean-Luc
Gh Paris Site Saint Joseph, Paris, France
Aron-Wisnewsky Judith
Aron-Wisnewsky Judith
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
Pfizer
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.
European journal of endocrinology   07 mars 2024
SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®
Essai Clinique (Hospices Civils de Lyon)   26 février 2024
Hyperphagia and impulsivity: use of self-administered Dykens' and in-house impulsivity questionnaires to characterize eating behaviors in children with severe and early-onset obesity.
Orphanet journal of rare diseases   23 février 2024
Corrigendum: Kidney disease in adults with Prader-Willi syndrome: international cohort study and systematic literature review.
Frontiers in endocrinology   22 janvier 2024
Management of Severe Malnutrition Post-bariatric Surgery Using Artificial Nutrition.
Obesity surgery   21 décembre 2023
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Essai Clinique (Rhythm Pharmaceuticals, Inc.)   09 novembre 2023
A novel pathogenic variant in MRAP2 in an obese patient with successful outcome of bariatric surgery.
European journal of endocrinology   07 novembre 2023
Serum Versus Fecal Calprotectin Levels in Patients with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the Prospective Leaky-Gut Study.
Obesity surgery   04 novembre 2023
Évaluation du bénéfice clinique après traitement par setmélanotide chez les patients atteints du syndrome de Bardet-Biedl (BBS)
39e congrès de la Société Française d'Endocrinologie 2023   01 octobre 2023
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity: An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation
Essai Clinique (Rhythm Pharmaceuticals, Inc.)   30 août 2023